We are on a mission to address the challenges that result from rapid changes in the science, technology and business of next-generation cancer care.

Trapelo Health Leadership

Clynt Taylor

Chief Executive Officer

Clynt Taylor is the Chief Executive Officer of Trapelo Health and a member of the company’s board of directors. He joined Insights in 2017 and brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies.


Since beginning his career at IBM, he’s held leadership roles at healthcare technology companies like NextGen, where he led sales and marketing teams; HealthVision as General Manager of its fastest growing division (purchased by Lawson) and Galvanon as Co-founder and CEO Healthcare Solutions (purchased by NCR). Most recently, he held various senior executive roles with NantHealth – including leading the innovation, launch and commercialization of eviti, Inc., recognized today as one of the nation’s premier oncology decision support solutions. Clynt is married with four children and lives in the Dallas area.

Russ Ingersoll, PhD

Chief Product Officer

Russell Ingersoll joined Trapelo Health in August, 2010, bringing 15 years of healthcare information technology experience and proven success with the design and commercialization of information-based technology products for the clinical and life science industries.


Prior to joining Intervention Insights, Russ served as VP of Product Development for MedTrust Online, an oncology-centric information portal; Senior Director of Business Development at Phylogeny, Inc., a functional genomics services company; co-Founder of Folio Biosciences, a biobank of clinically annotated specimens and co-founder of BioProtocol, an interactive laboratory protocol system for the research community. Russ received a BS in Molecular and Cellular Biology from the University of Arizona, a PhD in Pharmacology and Toxicology from the University of Arizona College of Pharmacy and completed his post-doctoral training at the University of California, Berkeley.

Ephraim Hochberg, MD

Chairman, Editorial Board and Sr. Clinical Advisor

Dr. Hochberg serves as a Senior Clinical Advisor and Chairman of the Editorial Board of Trapelo Health. Dr. Hochberg received his MD from Case Western Reserve University School of Medicine, Ohio in 1996. He completed an internship and residency at Brigham and Women’s Hospital, followed by a fellowship at the Dana Farber Cancer Institute. Dr. Hochberg is an Assistant Professor of Medicine at Harvard Medical School and is an attending physician at the Massachusetts General Hospital. He serves as the Clinical Director of Inpatient Oncology at the Massachusetts General Hospital Cancer Center.


With over 50 peer-reviewed publications and book chapters, he directs his research efforts towards novel therapies for Hodgkin and non-Hodgkin lymphomas. Additionally, he is a member of the NCCN Guideline Panel for Hodgkin Lymphoma.


Janine Morales, PhD

Senior Director Clinical Knowledge Systems

Janine Morales joined the Trapelo Health team in 2011 and oversees a team of editors and curators with deep expertise in molecular oncology. Her group is responsible for maintaining the company’s clinical information asset, a comprehensive knowledge-base summarizing published data pertaining to molecular biomarkers as predictors of response to targeted therapies in oncology. Janine also led the development of Intervention Insights’ framework for the systematic evaluation and synthesis of molecular clinical evidence as well as the principles guiding the presentation of molecular evidence in patient specific reports.


She brings 15 years of editorial and information management experience in the biotech and medical sectors and was a member of research and development teams at Elan Corp. and DNAX Research Institute (acquired by Merck & Co). Janine received a BS in Biochemistry from the University of Rochester and earned her PhD in Pharmacology from the University of California, San Francisco.


E. Jerome Madison

VP Pharma + Provider Relations

In addition to being the host of the award-winning Precision Medicine Podcast, Jerome Madison leads provider relations and lab integration at Trapelo Health. Jerome is a 14-year veteran of the precision cancer movement who has led the most successful companies in the genomic testing space to become market leaders. He helped create best practices for market access and adoption of clinical genomics and bring his vast network and knowledge to Intervention Insights to develop the network of providers to launch Trapelo. In addition to leading start-ups and building people in the industry, Jerome is also a certified executive coach, a published author and keynote speaker on the topic of innovation.


Dean Packer

VP of Payer + Provider Strategy

Dean Packer brings over 25 years of experience in healthcare innovation to the Trapelo Health team, both as an executive with startup and Fortune 500 companies. 


Over his extensive career, Dean has held various sales and leadership roles at healthcare companies like NantHealth, Best Doctors, Anthem BCBS, Keystone Health Plan Central and several pharmaceutical companies. Most recently, Dean helped NantHealth launch GPS Cancer to payers – a new program in precision care management. Dean earned a BS in Biology from Bloomsburg University in Pennsylvania and currently lives in Southern York County. 


DSC_6028 copy ps-.jpg

Lisa Long, JD

Senior Director Provider Network

Lisa Long has a rich background in oncology diagnostics and pharmaceuticals. As the former director of Eviti's Channel Partnerships & Business Development at NantHealth, Lisa identified and created alliances with resellers including pharmacy benefit managers and healthcare IT leaders for the company’s oncology services. Additionally, her work with Eviti’s pre-authorization tool expanded her knowledge of payer and provider needs.


Earlier in her career, Lisa launched molecular diagnostic tests at NantHealth and sold oncology products for Bristol Myers-Squibb and Sanofi Oncology. She has worked continuously to develop a deep understanding of the challenges faced by both providers and patients throughout her travels in the oncology community. As such, Lisa hosts a breast cancer survivors camp at her horse farm in Pennsylvania annually. In 2013, Lisa added a Juris Doctor of Law to her credentials. Her law school curriculum included a concentration in health law, specifically focused on the FDA, public access to medical care and disability law.


Karan Cushman

Chief Marketing Officer

Karan Cushman helps lead Trapelo Health in developing a user-centered interface, strategic marketing program and strong brand equity for its innovative precision medicine platform, Trapelo. She is also the producer of The Precision Medicine Podcast. She is a marketing, design, and user-experience veteran who has spent more than 20 years immersed in the health, life science, and biomedical industries. Her award-winning work in these industries has been recognized globally for driving engagement, support, and brand loyalty.

She is a certified IBM design-thinking facilitator, a graduate of Rochester Institute of Technology, and a cancer survivor.

Board of Directors

Lee_Newcomer zetema_Crop.png

Lee Newcomer, MD


Dr. Lee Newcomer recently retired from UnitedHealth Group, where he began his career in 1991 as the Chief Medical Officer for ten years. Dr. Newcomer practiced medical oncology in Minneapolis and Tulsa, Oklahoma. He served as the Medical Director for Cigna Healthcare, in Kansas City; and he was a founding executive of Vivius, a consumer-directed venture that allowed consumers to create their own personalized health plans. In 2006, Dr. Newcomer returned to UnitedHealth Group to lead a pilot initiative combining clinical, financial and program management experts to improve the quality and affordability of cancer care.  During that time the team launched the first risk payment program for cancer therapy, created a physician-oriented prior authorization tool, developed the first commercial database with clinical and claims data for cancer patients and launched a genetic test management program.

Dr. Newcomer holds a BA from Nebraska Wesleyan University, an MD from the University of Nebraska College of Medicine, and a Masters of Health Administration from the University of Wisconsin at Madison. His clinical training included an internal medicine residency at the University of Nebraska Medical Center and a medical oncology fellowship at the Yale University School of Medicine.

Harlan Levine Photo #2.jpg

Harlan Levine, MD


Dr. Harlan Levine is president of strategy and business ventures for City of Hope. In this role, he is accountable for strategy, innovation and growth, drug commercialization, payer strategies and the Center for International Medicine. He also serves as the chairman of the board of AccessHope, City of Hope’s wholly owned subsidiary focused on serving the employer market and making leading edge cancer care available to all regardless of geography.


Prior to City of Hope, Dr. Levine held executive roles at United Health Group, Towers Watson, and Anthem, Inc. He currently serves as a board member for BioScienceLA, Active Life Scientific, Trapelo Health, and Keck Graduate Institute’s Board of Trustees. He is a member of the Executive Advisory Council for California Lutheran University’s School of Management and is a Work Group Fellow for Health Evolution Forum’s New Models of Care Delivery.   He is certified by the American Board of Internal Medicine and licensed by the Medical Board of California.

Wright Steenrod


Wright Steenrod joined Chrysalis as an Associate in 2001 and today leads the Technology Group. Bringing his own entrepreneurial management experiences to the Chrysalis team, Wright previously worked as a senior business development executive at a rapidly growing company preparing to go public, and served as CFO of a start-up technology transfer company where he set strategic plans and raised equity and debt capital. Wright has worked with the management teams of fourteen of Chrysalis’ investments including Digitalsmiths (sold to TiVo), Advanced Academics (sold to DeVry), Genscape (sold to GFI) and Appriss (sold to Bain Capital), in the Technology portfolio among others. He currently is a Director of Cybera, Regent Education, Straighterline, Xlerant and meQuilibrium.


From 1995 to 1998, Wright worked at SunTrust Bank in Atlanta as an Associate in Mergers and Acquisitions. Prior to SunTrust, he served five years in the US Marine Corps where he attained the rank of Captain. Wright has a BA in Economics from Princeton University. He is a Louisville native and is active in the community working with organizations such as the Boys and Girls Clubs of Kentuckiana and Kentuckiana Works.

Michael Gross


Michael Gross is responsible for investment sourcing, deal execution and portfolio management, specifically for the InvestMichigan! Growth Capital Fund. He focuses on the healthcare and medical technology sectors and has expertise in medical devices, diagnostics, life science research, drug delivery, healthcare providers and outsourced services. Mr. Gross serves as a board director for Beringea portfolio companies Molecular Imaging, gloStream, Delphinus Medical Technologies, InTouch Health, Intervention Insights and Relume Technologies and is a board observer for Pioneer Surgical Technology and MedVantx.


Prior to joining Beringea, Michael was VP of investment banking with P&M Corporate Finance (PMCF). While at PMCF, he led M&A transactions and capital raises for companies in the life sciences, healthcare and outsourced business services sectors. Before working at PMCF, Michael worked in the investment banking group at Stout Risius Ross, Inc. He is a CFA charterholder and earned a BA in Finance from Michigan State University.

Clynt Taylor

Director, CEO

Clynt Taylor is the Chief Executive Officer of Trapelo Health and a member of the company’s board of directors. He joined Intervention Insights in 2017 and brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies.

Mark Olesnavage


Mark Olesnavage has led Hopen Life Sciences since 2006. A veteran of the pharmaceutical and nutraceutical industries, he has held senior management positions in business divisions in the United States, Europe and the Pacific Rim. He spent 24 years with Perrigo Company, where he held various senior management positions, including Executive Vice President and General Manager. During his tenure, he was involved in several key acquisitions and saw the company’s sales grow from $70 million to $1.3 billion (in 2005). Mark also was a driver in the development of numerous product and technology partnerships. He was a longtime member of the Generic Pharmaceutical Association and the Consumer Healthcare Products Association and has served on the executive committee of both groups. Prior to Perrigo, he held international marketing positions with Amway Corp.

Charlie Crawford


Charlie Crawford is an Associate at Chrysalis Ventures. He works with the management teams of existing Chrysalis investments across the firm’s focus areas of healthcare and technology and is currently a Director of Chrysalis’ portfolio company, NextImage Medical. Charlie is also actively involved in identifying new investment opportunities for Chrysalis.


Prior to Chrysalis, Charlie worked as a Senior Analyst at Innova Memphis, a Tennessee-based venture capital firm, where he was involved in the firm’s investments in healthcare services, technology and medical devices. Charlie received his BA with Honors from Williams College.

Clinical + Scientific Advisory Panel

Ravi Salgia, MD, PhD, Panel Chairman
City of Hope National Medical Center

Paul A. Bunn, Jr., MD
University of Colorado Cancer Center

Ephraim Hochberg, MD
Mass General Hospital, Harvard Medical School

Guido Marcucci, MD

City of Hope National Medical Center

R. Steven Paulson, MD
Texas Oncology

Editorial Panel

Ephraim Hochberg, MD, Panel Chairman
Mass General Hospital, Harvard Medical School

Alice Shaw, MD, PhD
Mass General Hospital, Harvard Medical School

Aditya Bardia, MBBS, MPH
Mass General Hospital, Harvard Medical School

Wolfram Goessling, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School

Paul A. Bunn, Jr., MD
University of Colorado Cancer Center

Harriet M. Kluger, MD
Yale University Cancer Center

Anna F. Farago, MD, PhD
Mass General Hospital, Harvard Medical School

Lead Investors


Is collaboration the key to improving cancer patient outcomes?

In this episode, Trapelo Health (formerly Intervention Insights) CEO Clynt Taylor discusses how one healthcare technology is bringing oncology stakeholders together to ease the burdens of prior authorization and speed patient care.